Arrowhead Pharmaceuticals(ARWR)

PASADENA, CAPharmaceutical1 H-1B visas (FY2023)

Focus: Arrowhead Pharmaceuticals is a public biotech company headquartered in Pasadena, CA, specializing in RNAi therapeutics for gene therapy and neurology indications. The company is generating ~$240M in annual revenue with a diversified pipeline of 23 programs across rare and chronic disease areas.

Gene Therapy Neurology

Profile data last refreshed Yesterday · AI intelligence enriched 2mo ago

Funding Stage

PUBLIC

Open Jobs

About Arrowhead Pharmaceuticals

AI assessmentNot Hiring

No open roles listed right now. Follow Arrowhead Pharmaceuticals to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

5/9 — Partial

Company HealthStrong

Pipeline

Late-stage

5 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Revenue

$241M

Key Products

REDEMPLO

Severe Hypertriglyceridemia; Familial Chylomicronemia Syndrome

Growth

Help build intelligence for Arrowhead Pharmaceuticals

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Leading RNAi platform with proven commercial traction: REDEMPLO (plozasiran) launched in 2025 for severe hypertriglyceridemia with 15-year exclusivity runway (LOE 2038)
Exceptional pipeline density with 23 programs spanning high-unmet-need areas (ALS, cystic fibrosis, obesity, Alzheimer's); 8 Phase 3/2 programs provide near-term clinical catalysts
Public company stability with $241M revenue and strategic R&D investment (147% intensity) signals commitment to innovation despite current losses

Pipeline & Clinical Trials

Orthopedic Surgery

Lactate Blood Increase

N/A

Clinical Trials (1)

NCT05611398Lactate Monitoring in Traumatic Long Bone Fractures Requiring Emergent Surgical Intervention

N/A

Boceprevir

Hepatitis C Infection

N/A

Clinical Trials (1)

NCT01465516Treating Hispanic Patients Diagnosed With Hepatitis C Using Boceprevir

N/A

Mortality and Morbidity Associated With New Onset Acute Kidney Injury in Critically Ill COVID-19 Inf

Acute Kidney Injury

N/A

Clinical Trials (1)

NCT05964088Mortality and Morbidity Associated With New Onset Acute Kidney Injury in Critically Ill COVID-19 Infection Patients

N/A

Difference in development of Acute Lung Injury in Amphetamine positive and negative patients

Burns

N/A

Clinical Trials (1)

NCT05611385Amphetamine Induced Adult Respiratory Distress Syndrome

N/A

Mindfulness

Depression, Unipolar

N/A

Clinical Trials (1)

NCT05400382Mindfulness to Reduce Post-cesarean Pain and Prevent Postpartum Depression

N/A

SUN

Opioid Use Disorder

N/A

Clinical Trials (1)

NCT06827288Adaptive Interventions for Emergency Department Patients With Opioid Use Disorder

N/A

No Intervention

COVID-19

N/A

Clinical Trials (1)

NCT05897528Insulin Regulation and Severity of Severe Acute Respiratory Syndrome COVID-19 Infection

N/A

No Intervention

COVID-19

N/A

Clinical Trials (1)

NCT05859958ABO Blood Group Type Association With COVID-19 Severity

N/A

Packed Red Blood Cell Administration

Trauma Injury

N/A

Clinical Trials (1)

NCT06402669Extremity Trauma At a Level 1 Trauma Center

N/A

No Intervention

Rectal Foreign Body

N/A

Clinical Trials (1)

NCT05888363Management and Removal of Foreign Bodies in the Emergency Department

N/A

Sofosbuvir and simeprevir

Hepatitis C

N/A

Clinical Trials (1)

NCT02485262Outcome of New Direct Acting Agents For Hepatitis C A Community Based Experience

N/A

Vitamin C

Burns

N/A

Clinical Trials (1)

NCT05612867Low Dose Vitamin C in Burns >20% Compared to Previous Studies With High Dose Vitamin C

N/A

ARO-SOD1

Amyotrophic Lateral Sclerosis

Phase 1

Clinical Trials (1)

NCT05949294Study of AROSOD-1 in Adult Participants With Amyotrophic Lateral Sclerosis (ALS)

Phase 1

VSA001 injection

Healthy Adult Volunteers

Phase 1

ARO-AAT Injection

Alpha 1-Antitrypsin Deficiency

Phase 1

Clinical Trials (1)

NCT03362242Study of ARO-AAT in Normal Adult Volunteers

Phase 1

ARO-HIF2

Clear Cell Renal Cell Carcinoma

Phase 1

Clinical Trials (1)

NCT04169711Study of ARO-HIF2 in Patients With Advanced Clear Cell Renal Cell Carcinoma

Phase 1

ARC-AAT Injection

Alpha-1 Antitrypsin Deficiency

Phase 1

Clinical Trials (1)

NCT02363946A Study of ARC-AAT in Healthy Volunteer Subjects and Patients With Alpha-1 Antitrypsin Deficiency (AATD)

Phase 1

ARC-521

Hepatitis B

Phase 1

Clinical Trials (1)

NCT02797522A Study of ARC-521 Injection in Normal Adult Volunteers and Patients With Chronic Hepatitis B (CHB)

Phase 1

ARO-APOC3

Hypertriglyceridemia

Phase 1

Clinical Trials (1)

NCT03783377Study of ARO-APOC3 in Healthy Volunteers, Hypertriglyceridemic Patients and Patients With Familial Chylomicronemia Syndrome (FCS)

Phase 1

Azithromycin Pill

Infections

Phase 1

Clinical Trials (1)

NCT06543290Azithromycin Before Induction

Phase 1

ARO-ATXN2

Spinocerebellar Ataxia Type 2

Phase 1

Clinical Trials (1)

NCT06672445Study of ARO-ATXN2 Injection in Adults With Spinocerebellar Ataxia Type 2

Phase 1

ARO-CFB

IgA Nephropathy

Phase 1

Clinical Trials (1)

NCT06209177Study of ARO-CFB in Adult Healthy Volunteers

Phase 1

ARO-ALK7

Obesity

Phase 1/2

Clinical Trials (1)

NCT06937203A First-In-Human Study of ARO-ALK7 in Adults With Obesity With and Without Type 2 Diabetes Mellitus

Phase 1/2

ARO-DIMERPA

Hyperlipidemia, Mixed

Phase 1/2

Clinical Trials (1)

NCT07223658Study of ARO-DIMERPA in Adult Participants With Mixed Hyperlipidemia

Phase 1/2

ARO-HSD

Non-alcoholic Steatohepatitis

Phase 1/2

Clinical Trials (1)

NCT04202354Study of ARO-HSD in Healthy Volunteers and Patients With Non-Alcoholic Steatohepatitis (NASH) or Suspected NASH

Phase 1/2

ARO-MAPT

Alzheimer Disease

Phase 1/2

Clinical Trials (1)

NCT07221344Study of ARO-MAPT-SC in Healthy Subjects and Subjects With Early Alzheimer's Disease

Phase 1/2

ARO-C3

C3 Glomerulopathy

Phase 1/2

Clinical Trials (1)

NCT05083364Study of ARO-C3 in Adult Healthy Volunteers and Patients With Complement Mediated Renal Disease

Phase 1/2

ARO-DM1

Myotonic Dystrophy 1

Phase 1/2

Clinical Trials (1)

NCT06138743Study of ARO-DM1 in Subjects With Type 1 Myotonic Dystrophy

Phase 1/2

ARO-DUX4

Facio-Scapulo-Humeral Dystrophy

Phase 1/2

Clinical Trials (1)

NCT06131983Study of ARO-DUX4 in Adult and Adolescent Patients With Facioscapulohumeral Muscular Dystrophy Type 1

Phase 1/2

ARO-MUC5AC

Chronic Obstructive Pulmonary Disease

Phase 1/2

Clinical Trials (1)

NCT05292950Study of ARO-MUC5AC in Healthy Subjects and Patients With Muco-Obstructive Lung Disease

Phase 1/2

ARO-RAGE

Asthma

Phase 1/2

Clinical Trials (3)

NCT07241546Study of Inhaled ARO-RAGE in Allergen-induced Mild Asthma

Phase 2

NCT05276570Study of ARO-RAGE in Healthy Subjects and Patients With Inflammatory Lung Disease

Phase 1/2

ARO-ENaC

Cystic Fibrosis

Phase 1/2

Clinical Trials (1)

NCT04375514Study of ARO-ENaC in Healthy Volunteers and in Patients With Cystic Fibrosis

Phase 1/2

ARO-MMP7

Idiopathic Pulmonary Fibrosis

Phase 1/2

Clinical Trials (1)

NCT05537025Study of ARO-MMP7 Inhalation Solution in Healthy Subjects and Patients With Idiopathic Pulmonary Fibrosis

Phase 1/2

ARO-INHBE

Obesity

Phase 1/2

Clinical Trials (1)

NCT06700538A First-In-Human Study of ARO-INHBE in Adults With Obesity With and Without Type 2 Diabetes Mellitus

Phase 1/2

ARO-HBV

Hepatitis B

Phase 1/2

Clinical Trials (1)

NCT03365947Study of ARO-HBV in Normal Adult Volunteers and Patients With Hepatitis B Virus (HBV)

Phase 1/2

fazirsiran

Alpha 1-Antitrypsin Deficiency

Phase 2

Clinical Trials (2)

NCT03946449Study of Fazirsiran (TAK-999, ARO-AAT) in Patients With Alpha-1 Antitrypsin Deficiency Associated Liver Disease (AATD)

Phase 2

NCT03945292Safety, Tolerability and Pharmacodynamic Effect of Fazirsiran (TAK-999, ARO-AAT)

ARO-ANG3

Dyslipidemias

Phase 2

Clinical Trials (3)

NCT05217667Study of ARO-ANG3 in Participants With Homozygous Familial Hypercholesterolemia (HOFH)

Phase 2

NCT04832971Study of ARO-ANG3 in Adults With Mixed Dyslipidemia

Phase 2

ARC-520

Hepatitis B

Phase 2

Clinical Trials (5)

NCT02604199A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Negative, Chronic Hepatitis B Virus (HBV) Infection

Phase 2

NCT02738008Extension Study of the Safety and Efficacy of Multi-dose Intravenous ARC-520 in Patients With Chronic Hepatitis B (HBV) Infection

ARO-APOC3

Severe Hypertriglyceridemia

Phase 2

Clinical Trials (4)

NCT05089084Study of ARO-APOC3 (Plozasiran) in Adults With Familial Chylomicronemia Syndrome (FCS)

Phase 3

NCT06347003Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia

Phase 3

ARC-AAT Injection

Alpha-1 Antitrypsin Deficiency

Phase 2

Clinical Trials (1)

NCT02900183Safety, Tolerability and Effect of ARC-AAT Injection on Circulating and Intrahepatic Alpha-1 Antitrypsin Levels

Phase 2

ARO-APOC3

Dyslipidemias

Phase 2

Clinical Trials (1)

NCT05413135Study of ARO-APOC3 in Adults With Dyslipidemia

Phase 2

Calcium carbonate

Uterine Contraction

Phase 2/3

Clinical Trials (1)

NCT07056062Oral Calcium Supplementation in Labor

Phase 2/3

zodasiran

Homozygous Familial Hypercholesterolemia

Phase 3

Clinical Trials (2)

NCT07473843Study of Zodasiran in Adolescent Participants With Homozygous Familial Hypercholesterolemia

Phase 3

NCT07037771A Phase 3 Study of Zodasiran in Adolescent and Adult Subjects With Homozygous Familial Hypercholesterolemia (YOSEMITE)

Tranexamic Acid

Hemorrhagic Shock

Phase 3

Clinical Trials (1)

NCT03469947California Prehospital and In Hospital Antifibrinolytic Therapy Via TXA

Phase 3

Venofer 200 MG Per 10 ML Injection

Iron Deficiency Anemia of Pregnancy

Phase 3

Clinical Trials (1)

NCT06366698Intravenous Iron Versus Oral Iron for the Treatment of Iron Deficiency Anemia

Phase 3

plozasiran

Severe Hypertriglyceridemia

Phase 3

Clinical Trials (5)

NCT06347016Study of Plozasiran in Adults With Severe Hypertriglyceridemia

Phase 3

NCT06347133Phase 3 Study of Plozasiran in Adults With Hypertriglyceridemia

Phase 3

Statins

Intracerebral Hemorrhage

Phase 3

Anti-hypertensive therapy

Hypertension

Phase 4

Bevacizumab

Pterygium

Phase 4

Clinical Trials (1)

NCT01736449Role of Sub-Conjunctival Bevacizumab in Post Pterygium Excision Management

Phase 4

Interview Prep Quick Facts

Portfolio: 1 approved product, 67 clinical trials

Top TAs: Infectious Diseases, Metabolic Diseases, Respiratory

H-1B (2023): 1 approval

SEC Filings: 2 available

Portfolio Health

Launch1 (100%)

1 total products

Therapeutic Area Focus

14 pipeline

8 pipeline

6 pipeline

4 pipeline

3 pipeline

Financials (FY2025)

Revenue

$241M1%

R&D Spend

$353M(147%)19%

Net Income

-$205M

Visa Sponsorship

Sponsors Work Visas

H-1B Petitions (FY2023)

Approved

Denied

100%

Rate

Source: USCIS H-1B Employer Data Hub

Arrowhead Pharmaceuticals(ARWR)

About Arrowhead Pharmaceuticals

Why Work Here

Key Products

Watch Out For

Products & Portfolio (1)

Pipeline & Clinical Trials

Recent News · Arrowhead Pharmaceuticals(10)

Open Jobs (0)

Financials (FY2025)

Visa Sponsorship